| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/12/2001 | WO2001049713A2 Stabilizing peptides, polypeptides and antibodies which include them |
| 07/12/2001 | WO2001049711A2 Nucleic acids encoding (poly)peptides having chips activity |
| 07/12/2001 | WO2001049705A2 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent |
| 07/12/2001 | WO2001049698A1 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| 07/12/2001 | WO2001049696A1 N,o-amidomalonate platinum complexes |
| 07/12/2001 | WO2001049691A1 CAMPTOTHECIN β-ALANINE ESTERS WITH TOPOISOMERASE I INIBHITION |
| 07/12/2001 | WO2001049689A2 NOVEL SUBSTITUTED PYRAZOLO[4,3-e]DIAZEPINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, USE AS MEDICINAL PRODUCTS AND PROCESSES FOR PREPARING THEM |
| 07/12/2001 | WO2001049688A1 Purine derivatives, process for their preparation and use thereof |
| 07/12/2001 | WO2001049684A1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same |
| 07/12/2001 | WO2001049675A1 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders |
| 07/12/2001 | WO2001049674A2 Glycosidase inhibitors and preparation thereof |
| 07/12/2001 | WO2001049673A2 Compounds and methods for modulation of estrogen receptors |
| 07/12/2001 | WO2001049661A1 5-THIA-φ-(SUBSTITUTED PHENYL)-PROSTAGLANDIN E ALCOHOLS, PROCESS FOR PREPARING THE ALCOHOLS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT |
| 07/12/2001 | WO2001049318A1 Novel chimeric proteins and methods for using the same |
| 07/12/2001 | WO2001049317A2 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen |
| 07/12/2001 | WO2001049312A2 O-superfamily conotoxin peptides |
| 07/12/2001 | WO2001049308A1 Novel immune enhancing compositions |
| 07/12/2001 | WO2001049306A1 Balanites aegyptiaca extracts for treatment of hiv/aids and leukemia |
| 07/12/2001 | WO2001049305A2 Process for obtaining thylakoids from plants, pure thylakoids and use thereof |
| 07/12/2001 | WO2001049303A1 Multivalent electron active compositions and methods of making and using same |
| 07/12/2001 | WO2001049302A1 Compositions and methods for facilitating skin growth and managing skin conditions |
| 07/12/2001 | WO2001049301A1 Methods of using electron active compounds for managing cancer |
| 07/12/2001 | WO2001049295A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/12/2001 | WO2001049294A1 Product for treating gynecomastia |
| 07/12/2001 | WO2001049291A1 10,11-difluoromethylenedioxycamptothecin compounds with topoisomerase i inhibition |
| 07/12/2001 | WO2001049290A1 Methods and reagents for facilitating transcription |
| 07/12/2001 | WO2001049288A1 Novel compounds and compositions as protease inhibitors |
| 07/12/2001 | WO2001049287A1 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/12/2001 | WO2001049281A2 POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES |
| 07/12/2001 | WO2001049279A2 Use of steroidal alkaloids to reverse multidrug resistance |
| 07/12/2001 | WO2001049274A2 Methods for pulmonary delivery of interleukin-2 |
| 07/12/2001 | WO2001049268A1 Pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| 07/12/2001 | WO2001049163A1 Pp14 fusion proteins and methods for making and using the same |
| 07/12/2001 | WO2001044207A8 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 07/12/2001 | WO2001012665A3 Helical cytokine zalpha48 |
| 07/12/2001 | WO2001007087A8 Enzyme catalyzed anti-infective therapeutic agents |
| 07/12/2001 | WO2000074724A3 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 07/12/2001 | WO2000074722A3 Modification of biological elements |
| 07/12/2001 | WO2000055318A8 Abc1 polypeptide and methods and reagents for modulating cholesterol levels |
| 07/12/2001 | WO2000041726A9 Noninvasive vascular therapy |
| 07/12/2001 | WO2000034447A8 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 07/12/2001 | WO2000000510A3 Growth factor modulators |
| 07/12/2001 | WO1999052541A3 Artery- and vein-specific proteins and uses therefor |
| 07/12/2001 | US20010007902 An oligonucleotide complementary to a region of the ribonucleotide component of telomerase attached to an activator of ribonuclease L (activator-antisense complex) which cleaves ribonuclotide portion of telomerase enzyme |
| 07/12/2001 | US20010007870 Compounds useful for inhibition of farnesyl protein transferase |
| 07/12/2001 | US20010007693 Food products having enhanced cocoa polyphenol content and processes for producing the same |
| 07/12/2001 | DE19963859A1 Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen Bi- or oligomer of a di-, tri-, Quattro or pentamer of recombinant fusion proteins |
| 07/12/2001 | DE19962828A1 Screeningsverfahren für Chemotherapeutika Screening method for chemotherapeutic agents |
| 07/12/2001 | CA2475413A1 Compositions and methods for treating conditions responsive to estrogen |
| 07/12/2001 | CA2475393A1 Compositions and methods for treating conditions responsive to estrogen |
| 07/12/2001 | CA2397714A1 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent |
| 07/12/2001 | CA2396688A1 Glycosidase inhibitors and methods of synthesizing same |
| 07/12/2001 | CA2396529A1 O-superfamily conotoxin peptides |
| 07/12/2001 | CA2396401A1 Novel fgf homolog zfgf12 |
| 07/12/2001 | CA2396399A1 Methods for protein transfer |
| 07/12/2001 | CA2396393A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/12/2001 | CA2396315A1 Novel substituted pyrazolo[4,3-e]diazepines, pharmaceutical compositions containing them, use as medicinal products and processes for preparing them |
| 07/12/2001 | CA2396276A1 Purine derivatives, process for their preparation and use thereof |
| 07/12/2001 | CA2396257A1 Novel compounds and compositions as protease inhibitors |
| 07/12/2001 | CA2396239A1 Novel immune enhancing compositions |
| 07/12/2001 | CA2396114A1 Methods of modulation of the immune system |
| 07/12/2001 | CA2396059A1 Compounds and methods for modulation of estrogen receptors |
| 07/12/2001 | CA2395945A1 Novel chimeric proteins and methods for using the same |
| 07/12/2001 | CA2395887A1 Methods for pulmonary delivery of interleukin-2 |
| 07/12/2001 | CA2395876A1 Nucleic acids encoding (poly)peptides having chips activity |
| 07/12/2001 | CA2395795A1 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders |
| 07/12/2001 | CA2395660A1 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| 07/12/2001 | CA2395642A1 Use of steroidal alkaloids to reverse multidrug resistance |
| 07/12/2001 | CA2395625A1 Progenitor cell preservation factors and related methods and products |
| 07/12/2001 | CA2395198A1 Pp14 fusion proteins and methods for making and using the same |
| 07/12/2001 | CA2395132A1 Pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| 07/12/2001 | CA2395041A1 Stabilizing peptides, polypeptides and antibodies which include them |
| 07/12/2001 | CA2394721A1 Product for treating gynecomastia |
| 07/12/2001 | CA2394597A1 Enhancing the immune response to an antigen by presensitizing with an inducing agent prior to immunizing with the inducing agent and the antigen |
| 07/12/2001 | CA2331059A1 Method of reducing morbidity and the risk of mortality |
| 07/11/2001 | EP1114829A2 Alloferons - Immunomodulatory peptides |
| 07/11/2001 | EP1114826A2 Novel antibacterial and prokinetic macrolides |
| 07/11/2001 | EP1114164A1 Atp synthase subunit homolog |
| 07/11/2001 | EP1114159A1 Methods and compositions relating to egf-repeat-containing polypeptides |
| 07/11/2001 | EP1114158A2 Human cytoskeleton associated proteins |
| 07/11/2001 | EP1114155A2 Human gpcr proteins |
| 07/11/2001 | EP1114146A2 Human serine/threonine protein kinases |
| 07/11/2001 | EP1114144A1 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 07/11/2001 | EP1114063A2 A method of producing a functional immunoglobulin superfamily protein |
| 07/11/2001 | EP1114053A1 Pyrrolopyrimidines as protein kinase inhibitors |
| 07/11/2001 | EP1114052A1 4-aminopyrrolopyrimidines as kinase inhibitors |
| 07/11/2001 | EP1114051A1 INHIBITORS OF p38 |
| 07/11/2001 | EP1114048A1 Carboline derivatives as cgmp phosphodiesterase inhibitors |
| 07/11/2001 | EP1114039A1 INHIBITORS OF p38 |
| 07/11/2001 | EP1114031A1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 07/11/2001 | EP1114029A1 Novel compounds |
| 07/11/2001 | EP1113821A1 In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
| 07/11/2001 | EP1113820A1 Expandible microparticle intracellular delivery system |
| 07/11/2001 | EP1113810A2 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| 07/11/2001 | EP1113809A2 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor |
| 07/11/2001 | EP1113800A1 Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents |
| 07/11/2001 | EP1113795A2 Tryptophanyl ester and their n-acyl derivatives for the prevention and treatment of diseases caused or exacerbated by oxidation processes |
| 07/11/2001 | EP0912509B1 Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents |
| 07/11/2001 | EP0758231B1 Taxane class derivative based pharmaceutical compositions |
| 07/11/2001 | EP0735876B1 Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin |